Flywheel, the leading medical imaging data management and analysis platform, today announced key milestones achieved in 2025. The company also recently closed on an oversubscribed $25 million financing round, led by Novalis Lifesciences and 8VC.
Flywheel has evolved from its origin as a technology platform designed to support core lab research to an enterprise imaging management platform designed to support clinical trials, medical device development and AI innovation through at-scale data aggregation, curation and analysis.
Read More – Onsetto Raises $2.2M in Seed Funding
Over the past year, Flywheel expanded its core capabilities by launching video viewing and annotation tools, along with Flywheel Validated, a solution that streamlines 21 CFR Part 11 compliant workflows for clinical trials. Together, these capabilities are designed to enable earlier access to imaging data with provenance, reduced costs and improved quality — ultimately helping accelerate time to decision and time to market.
“Imaging data holds tremendous value and is increasingly viewed as a strategic asset. Unlocking this value requires more than just a foundational infrastructure to aggregate data. It involves integrated data management, curation, compliant workflows and AI capabilities, along with access to a connected healthcare ecosystem — all at scale.
Flywheel is well-positioned to uniquely transform how companies can maximize value from their imaging assets by better informing clinical trials, accelerating AI development and enabling research and clinical teams to move faster from discovery to decision,” said Hooman Hakami, Flywheel CEO and Board Chair.
Read More – Apella Raises $80M in Series B Equity and Venture Debt
